NICE amends Alzheimer's guidance

Treatments for Alzheimer's disease can now be prescribed on the NHS for a broader range of patients.

Previous NICE guidance restricted medication access to patients with moderate disease | SPL
Previous NICE guidance restricted medication access to patients with moderate disease | SPL

The acetylcholinesterase inhibitors donepezil (Aricept), galantamine (Reminyl) and rivastigmine (Exelon) are now recommended by NICE as options for managing mild as well as moderate Alzheimer’s disease. The NMDA antagonist memantine (Ebixa) is recommended as an option for patients with moderate Alzheimer’s disease who cannot take acetylcholinesterase inhibitors, and as an option for severe Alzheimer’s disease.

Treatment should be initiated and reviewed regularly by a specialist and continued only if it improves cognitive, global, functional or behavioural symptoms.

The decision to expand NHS reimbursement of these agents took into account growing clinical evidence of their benefit and accumulating information about the costs of Alzheimer’s disease, said NICE.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases